Summary Malignant tumours contain normal cells, descendants of transformed cells, and conceivably also initiated cells which have taken some but not all of the steps toward malignancy, and hybrid cells. Tumours are propagated by multiplication of clonogenic cells, which are a subclass of the descendants of transformed cells. The clonogenic cells of a tumour may differ in respect of morphology, karyotype, metastatic capacity, sensitivity to cytotoxic drugs, expression of cell surface antigens and hormone receptors, immunogenicity, sensitivity to the immune reaction of the host, and other properties. Evidence (disputed by some) suggests that selection of particular subpopulations plays a role in tumour metastasis and recurrence. Heterogeneity may be due to pleoclonal origin, generation of phenotypic diversity within a clone, or spontaneous hybridization and chromosome loss. The possibility of interaction between different subpopulations must be taken into account in discussing tumour cell population kinetics. Heterogeneity also has important therapeutic implications and may help to explain the failure of some therapeutic regimes and the success of others.
A malignant tumour what biologists are apt to call, redundantly, a solid malignant tumour-is not just a collection of neoplastic cells but a complex structure whose cell population includes normal cells derived from normal progenitors as well as the descendants of one or more transformed cells. It may conceivably also include cells which have taken one or more, but not all, of the steps on the way to malignancy, which I shall refer to as initiated cells (or part way cells), and hybrid cells, formed by the fusion of two cells of the same or different kinds.
The normal cells derived from normal progenitors include leucocytes of various kinds, macrophages, fibroblasts and endothelial cells. Their presence and behaviour in tumours are of great interest but I shall not discuss them in this review except to point out that methods of analysis which fail to detect these cells may also fail to detect particular subpopulations of malignant cells.
The descendants of transformed cells include proliferating cells in various stages of the cell cycle, so called Go cells which have stopped cycling temporarily but may later re-enter the cycle, and end state cells which are incapable of further division. Proliferating cells from which a tumour may be propagated in the autochthonous or another host, or in tissue culture, I shall refer to as clonogenic cells. I shall avoid using the, to me, fuzzy term tumour stem cell. If this is used to denote a clonogenic cell it is redundant; if used as a restricted class of clonogenic cell it is unhelpful unless this class is clearly defined. If, as sometimes happens, it is used to denote those cells of a Received 17 January 1983; accepted 31 January 1983. tumour which happen to possess the modal number of chromosomes, it is misleading.
An important question is whether the descendants of transformed cells can lose their malignant characteristics but continue to proliferate. We know from studies by Mintz and her colleagues (Mintz & Illmensee, 1975; Mintz, 1978) of mice produced in foster mothers from blastocysts injected with one or more cells of a teratocarcinoma that had been induced and maintained by serial transplantation in a different strain, that a single teratocarcinoma cell can, under these conditions, give rise to the whole gamut of normal somatic tissues and also to fully functioning spermatozoa. But can the cells of this and other tumours give rise to proliferating non-malignant cells in the autochthonous host? I heard this question asked by Ralston Paterson 35 years ago when discussing the source of the new epithelium in a patient whose large ulcerating squamous cell carcinoma had healed following radiotherapy. We are still awaiting a definite answer, but with the markers now available it should be possible to obtain this, at least in respect of mouse tumours. (Dexter et al., 1978) , metastatic capacity as judged either by the development of spontaneous metastases (Fidler & Kripke, 1977; Kripke et al., 1978) or by lung colony formation after i.v. injection of tumour cells (Fidler & Kripke, 1971; Kripke et al., 1978; Suzuki et al., 1978; Fidler et al., 1981) , the presence of hormone receptors (Sluyser & van Nie, 1974) , sensitivity to cytotoxic drugs (Barranco et al., 1972 (Barranco et al., , 1973 Hakansson & Trope, 1974; Trope, 1975; Houghton et al., 1976; Donelli et al., 1977) , expression of surface antigens (Prehn, 1970; Byers & Johnson, 1977; Killion 1978; Miller & Heppner, 1979; Olsson & Ebbesen, 1979) , immunogenicity and/or responsiveness to the immune reaction of the host (Prehn, 1970; Miller & Heppner, 1979; Miller et al., 1980) , tumorigenic capacity on transplantation (Schmitt & Daynes, 1981; Woodruff et al., 1982) , and morphology and growth rate in tissue culture (Dexter et al., 1978) . The role of selection of particular subpopulations in tumour metastasis, and in the recurrence of tumours after incomplete ablation, is controversial. Alexander (1982) , in the light of experiments in which pulmonary metastases from transplanted rat fibrosarcomas showed no greater metastatic capacity when retransplanted than transplants of the primary tumour, concluded that "the fate of cells shed from the tumour is determined by anatomical and host factors, and metastasis appears to be a stochastic rather than a selective process". But failure to find evidence of selection in a particular experimental model does not justify such a far reaching conclusion, and others have reported the existence of phenotypic differences between cells of a primary tumour and those of a local recurrence (Pimm & Baldwin, 1977) or metastasis (Baylin et al., 1978; Fogel et al., 1979) , and between different metastases of the same tumour (Albino et al., 1981) . Such differences are not surprising when one considers the magnitude of the environmental change to which a cell must adapt when it is transported to a new site or caught up in the local inflammatory reaction which follows attempted ablation, by whatever means, of a primary tumour.
Much of this work has been done with animal tumours, including mouse fibrosarcomas, mammary carcinomas, leukaemias and melanomas, and the Lewis lung tumour, and rat fibrosarcomas, but some relates to human tumours. Here are some examples: 1. Barranco et al. (1972 Barranco et al. ( , 1973 .
The gene products studied may be located on the cell surface or within the cell, or externally secreted.
In the special case of immunoglobulin-producing tumours the characteristics of the immunoglobulin are normally used.
With human solid tumours which do not secrete immunoglobulin many studies of clonality have been based on the mosaicism which exists in the normal tissues of women who are heterozygous for the two forms of the enzyme glucose-6-phosphate dehydrogenase (G-6-PD). This mosaicism results from the inactivation of one X-chromosome in all somatic cells, and should not exist in a monoclonal population. As a result of the work of Fialkow and others with this marker (Fialkow, 1976) , it has become widely accepted that most, though not all, human solid tumours are monoclonal in origin, but interpretation of the data is not as straightfoward as it appears. On the one hand, a pleoclonal tumour may appear to be monoclonal because it has arisen from a "patch" of transformed cells of the same type or because it contains subpopulations too small to be detected; on the other hand, a monoclonal tumour may appear to be polyclonal because of the presence of non-neoplastic cells in the population tested. Moreover, a tumour which is monoclonal when tested may have been polyclonal at an earlier stage in its life history.
In the hope of resolving these doubts, people have looked for animal models to study. Isoenzymes of G6PD have been identified in Mus Caroli but unfortunately not in Mus musculus. A few years ago, however, an electrophoetic variant (A) of the X-coded enzyme phosphoglycerate kinase-l (PGK-1) which differs from the B form found in common laboratory strains of Mus musculus, was found in a feral mouse of this species. Following this discovery, Reddy & Fialkow (1979) reported that fibrosarcomas induced chemically in female hybrids of feral and laboratory-bred mice expressed both forms of the enzyme and were therefore polyclonal, but the conclusion that both isoenzymes were produced by neoplastic cells was based solely on morphological evidence. To overcome this limitation, my colleagues and I (Woodruff et al., 1982) have induced fibrosarcomas in genetically standardized female mice expressing both alloenzymes (AB mice), obtained by crossing normal CBA mice which express only the B form of the enzyme (B mice) with CBA backcross mice expressing only the A form (A mice). Enzyme assays were performed not only on freshly removed primary tumours but also on tumours, and clones derived from them, which had been maintained in tissue culture or transplanted to histocompatible A mice or B mice.
Cell suspensions from whole tumours often yielded both alloenzymes: suspension from tissue cultures of primary tumours did so less often. We attribute this difference to the elimination of leucocytes, which do not adhere to tissue culture flasks and were discarded, and macrophages, which adhere so strongly that they were left behind when the tumour cells were harvested. With many tumours the A/B ratio fluctuated markedly in the course of tissue culture. In some cases a component which was predominant initially later disappeared completely; in others a component which was not detected initially appeared later and eventually predominated. A clones and B clones were isolated from some tumours and were proved to be tumorigenic by transplantation. Although whole tumour suspensions regularly gave rise to tumours in normal mice many individual clones failed to do so; they did grow, however, in thymectomized, irradiated mice, and, after passage in such mice, usually grew in normal mice. This suggests that cells with a high capacity for survival are selected when a pleoclonal population is transplanted or, alternatively, that some clones require the cooperation of others to survive. Clones which expressed both A and B were isolated from one tumour. The significance of this observation is discussed below.
Taken as a whole the results highlight the problems involved in assessing the clonal status of tumours with X-linked markers, and raise doubts about the validity of some of the conclusions based on G-6 PD studies of human tumours.
The generation of diversity within clones
It has been reported that isolated tumour clones soon become heterogeneous in respect of many of the properties listed earlier when they are transplanted or maintained in tissue culture (Fidler & Hart, 1982) . This has been reported with various tumours; the one which has been most widely used is the B 16 mouse melanoma, and the property which has been most studied is the capacity of tumour cells to produce disseminated tumour foci after i.v. injection. In experiments with a murine lymphoma, however, Chow & Greenberg (1980) found that whereas heterogeneity in respect of one particular marker susceptibility to killing by naturally occurring cytotoxic antibodies developed during a single passage in vivo, it did not do so in vitro, and they concluded, that host factors may contribute in some way to the generation of diversity.
In contrast to the instability of cloned populations, the composition of the original heterogeneous uncloned population may remain remarkably constant under similar conditions. Poste et al. (1981) , who first reported this, suggested that in polyclonal populations the various subpopulations interact in such a way as to stabilize their relative proportions within the population as a whole.
Spontaneous hybridization
As mentioned previously, in our experiments with fibrosarcomas induced in mice heterozygous for the two forms of PGK-1, numerous "clones" which expressed both A and B alloenzymes were isolated from one tumour. After recloning at extreme dilution (on average 0.3 clonogenic cells per well) and again after passage in mice, 50 reclones still expressed both A and B, 6 expressed B only, and none expressed A only. It seems clear that our "clones" were indeed true clones and not mixtures of A cells and B cells. It seems most likely that they arose by spontaneous hybridization of cells of different enzyme phenotypes; it is just possible that they arose from cells in which chromosome replication had occurred without cell division and a previously inactive X-chromosome had become reactivated. We attribute the loss of the A component in some cases to selective chromosomal loss. The cells of the AB clones were markedly polyploid. Cells from uncloned tumours and clones expressing only one enzyme phenotype were, however, usually also polyploid, and we are presently engaged in a comparative study of the karyotypes of these various categories of cell.
Some years ago Wiener et al. (1972) , using the T6 translocation as marker, obtained evidence of spontaneous fusion of transplanted murine tumour cells and host cells. Subsequently, Lala et al. (1980) The existence of different subpopulations increases the chance that cells with a high probability of survival will be selected when environmental conditions change. It may thus facilitate metastasis (Poste & Fidler, 1980) and local recurrence of a tumour, and may help to explain the rapid development of metastases from cells which have remained dormant long after successful ablation of the primary tumour (for review see Woodruff, 1981) .
Little is known about the mechanisms involved in interactions between tumour cell subpopulations, but it is possible to make some plausible conjectures. Sporn & Todaro (1980) that tumour cells are stimulated by polypeptides which they themselves produce. The capacity of tumour cell populations to diversify may however elude even "broad spectrum" therapy. This may conceivably explain why adjuvant chemotherapy has so far met with such limited success in preventing the development of metastases after removal of a primary tumour.
If, as I believe, there is still much to be learned about cancer at the cellular level, it seems likely that one area in which important advances will be made will be made will be the study of cellular heterogeneity in tumours.
We have, slowly, come to accept the notion that cancer is not one disease but many. We must now face the possibility that a single patient with cancer may have many diseases. Such a reappraisal may be agonizing, but without pain there can be no progress.
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